Recent Healthcare Financings
| Company Name | Amount Raised | Type of Fundraise | Country | Date |
| Private Company Financings | ||||
| QL Biopharm | $72 million | Series C | China | 2 March |
| Prolium Biosciences | $50 million | Series A | US | 3 March |
| Atavistik Bio | $40 million | Series B | US | 5 March |
| Tacit Therapeutics | $19 million | Series A | US | 9 March |
| Unnatural Products | $45 million | Series B | US | 16 March |
| R1 Therapeutics | $77.5 million | Series A | US | 17 March |
| Crossbow Therapeutics | $77 million | Series B | US | 18 March |
| Immutrin | $87 million | Series A | UK | 24 March |
| Gilgamesh Pharma | $60 million | Series A | US | 25 March |
| Ambrosia Biosciences | $100 million | Series B | US | 31 March |
| Public Company Financings | ||||
| MAIA Biotechnology | $30 million | Public offering | US | 2 March |
| Teva Pharmaceuticals | $400 million | N/A | US | 3 March |
| Minimed | $560 million | Public offering | US | 5 March |
| Solid Biosciences | $240 million | Private placement | US | 6 March |
| Korro Bio | $85 million | Private placement | US | 9 March |
| Relmada Therapeutics | $160 million | Private placement | US | 9 March |
| Longeveron | $30 million | Private placement | US | 10 March |